Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05443581
Other study ID # XH-22-004
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 1, 2022
Est. completion date May 2024

Study information

Verified date November 2023
Source Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Contact Xiuhua Shen, Professor
Phone +86-139-1691-0428
Email srachel@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, 18-60 years old patients with metabolic associated fatty liver disease(MAFLD) will be recruited to test the intervention effect of vegetarian diet. This randomized clinical trial randomized individuals to a healthy vegetarian diet or a healthy omnivorous diet for 24 weeks. At the baseline and after the 24week intervention, the clinical manifestations of MAFLD, obesity levels, indices for glucose and lipid metabolism parameters, results of questionnaire and fecal samples will be collected and analyzed.


Description:

Dietary control remains an important way for nutritional intervention of metabolic related fatty liver disease. However, studies shows that patients have low compliance to the traditional diet. The topic proposed based on previous studies,recruiting of 220 obesity patients with metabolic associated fatty liver disease aged 18-60. After the informed consent, they will be randomly divided into intervention group and control group, intervention group will be given healthy vegetarian diet intervention and the control group given healthy omnivorous diet. Both diets are in line with the principles of fatty liver treatment. Interventions consisted primarily of face-to -face interview monthly and online interview every 2 weeks, which will be performed by professional dietitians. All participants were asked not to alter their exercise patterns during the study period. The primary outcome was the weight of fat mass after 24 weeks intervention. Secondary outcomes included imaging findings (B-ultrasonic examination and Fibroscan) of MAFLD, liver function, anthropometric measures, plasma lipid and glucose levels. At the meantime, serum oxidative stress indices, results of compliance survey and metabolites of Intestinal flora will be collected and analyzed. Through the above detection of the indicators related to MAFLD and obesity, it is explored whether the vegetarian diet can be an efficient and feasible way to the nutritional therapy of MAFLD.


Recruitment information / eligibility

Status Recruiting
Enrollment 220
Est. completion date May 2024
Est. primary completion date May 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Clinically diagnosed as fatty liver, and BMI=24.0kg/m²; 2. 18-60 years old; 3. Have not received drug treatment if having hyperglycemia, hyperlipidemia and high uric acid ; 4. No antibiotics in the last 1 month; 5. The guardian's informed consent; Exclusion Criteria: 1. Have received drug treatment of fatty liver disease within three months; 2. Patients with with liver cirrhosis, viral hepatitis and other liver diseases; 3. Patients with serious heart, lung, kidney diseases and patients with cancer; 4. Pregnant and nursing women; 5. Other conditions that may affect the results of the study

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
dietary intervention
Dietary guidance will be given to participants through monthly face-to-face interviews and biweekly telephone calls to change their dietary structure and energy intake.

Locations

Country Name City State
China Department of Clinical Nutrition, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other The Results of compliance survey will be collected every month. We have designed a compliance scale to evaluate the compliance , which may be important to advise the nutritionists and doctors about the prevention and treatment of MAFLD. 24 weeks
Other The difference of serum superoxide dismutase (SOD) level between two groups after 24-week intervention Cause vegetarian diet may contain more phytochemicals and less saturated fat and cholesterol due to the plant-based nature of the diet, resulting in better metabolic status and milder metabolic burden,we have presumed that the serum SOD level be different between two groups at the end of study. 24 weeks
Other The difference of metabolites of Intestinal flora between two groups after 24-week intervention. The fecal samples before and after the intervention to examine the effect of vegetarian diets on gut microbiota metabolites. 24 weeks
Primary The primary outcome was the weight of fat mass after 24 weeks intervention. Weight loss, especially the reduction of body fat mass, is the most important treatment for the prevention and treatment of MAFLD and its complicationsIn our study, we will measure weight of fat mass using a body composition analyzer (Biospace Inbody 720, Korea) at the baseline and after 24-week intervention. The difference in the weight of fat mass after intervention between the two groups is the primary outcome. 24 weeks
Secondary Results of B-ultrasonic examination and Fibroscan examination Imaging examination results are an important basis for the clinical diagnosis of NAFLD, which can show the degree of hepatic steatosis and hepatic fibrosis. Imaging findings of MAFLD will be measured and compared at the baseline and end of our study. 24 weeks
Secondary The changes of serum alanine aminotransferase (ALT) at week 24 intervention from the baseline Hepatic steatosis is often accompanied by changes in hepatic enzymes. 24 weeks
Secondary The changes of serum aspartate aminotransferase (AST) at week 24 intervention from the baseline Hepatic steatosis is often accompanied by changes in hepatic enzymes. 24 weeks
Secondary 24-week weight change The 24-week intervention is expected to bring weight loss. We will compare the weight loss between the two groups 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2